AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the French Health Authority (ANSM)

Source: Nasdaq GlobeNewswire / 03 Jan 2022 09:10:59   America/Los_Angeles